Centre for Aquaculture Technologies Welcomes Matt Kramer as Senior Vice President of Global Sales and Marketing

New Leadership in Aquaculture Innovation

The Centre for Aquaculture Technologies (CAT) has announced the appointment of Matt Kramer as its Senior Vice President of Global Sales and Marketing. In this pivotal role, Matt will spearhead the company’s efforts to expand its innovative solutions in genetic improvement, focusing particularly on commercial-scale genome editing for the aquaculture industry.

A Proven Leader in Genomics

With over two decades of experience in driving commercial growth across various sectors in genomics and life sciences, Matt is well-equipped to lead CAT into its next phase. His impressive background includes significant roles at industry giants such as QIAGEN, ThermoFisher, Element Biosciences, and Psomagen, where he successfully implemented transformative sales strategies and cultivated high-performing teams.

Diverse Expertise Across the Commercial Spectrum

Matt’s extensive expertise encompasses sales, marketing, and product management, with a strong foundation in genomics, molecular diagnostics, and next-generation sequencing technologies. This breadth of knowledge positions him to navigate the complex landscape of aquaculture and effectively communicate the benefits of genome editing to stakeholders.

A Vision for the Future

Expressing his enthusiasm for this new opportunity, Matt Kramer stated:

“I was drawn to this role for its combination of strategic scope and purpose — with the opportunity to help shape how genomic and genome-editing technologies transition from research tools into real-world impact. CAT’s culture, scientific expertise, and long-term vision align strongly with my own values as a leader.”

He further emphasized the transformative potential of genome editing for the aquaculture industry:

“Genome editing offers transformative benefits by enabling targeted genetic improvements that enhance operational productivity, resilience, and sustainability. As the global population grows, CAT’s genome editing services provide a safe and effective way to increase the availability of nutritious food while reducing pressure on wild fish stocks.”

Support from Leadership

Dr. John Buchanan, CEO of CAT, expressed his enthusiasm for Matt’s appointment, stating:

“We are pleased to have Matt join our team. His experience and leadership will be instrumental in expanding the commercialization of genome editing in aquaculture globally. Together with our team, I am confident that we will propel CAT into an exciting new era of innovation, productivity, and sustainability.”